Lantheus
LNTH
Collegium Pharmaceutical
COLL
星座品牌
STZ
奥洛兹美医疗
HALO
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
美股市场个股详情
EXEL 伊克力西斯
- 39.155
- +0.575+1.49%
收盘价 03/10 16:00 (美东)
- 39.160
- +0.005+0.01%
盘后 20:01 (美东)
109.59亿总市值22.25市盈率TTM
40.020最高价38.240最低价387.87万股成交量38.240今开38.580昨收1.53亿成交额1.64%换手率22.25市盈率(静)2.80亿总股本40.02052周最高4.88市净率92.36亿流通值20.14052周最低--股息TTM2.36亿流通股50.500历史最高--股息率TTM4.61%振幅1.260历史最低39.495平均价1股每手
关于伊克力西斯公司
Exelixis Inc是一家发现、研发并将癌症治疗方法商业化的生物制药公司。其研发的分子药物cabozantinib，以商品名 “Cometriq” 用于治疗转移性甲状腺髓样癌患者，以商品名 “Cabometyx” 用于治疗肾癌和肝癌。Exelixis及其合作伙伴Roche还将Cotellic推向市场，用于治疗黑色素瘤。
公司介绍
公司代码EXEL
公司名称伊克力西斯
上市日期2000/04/11
发行价格13.00
成立日期1994
CEODr. Michael M. Morrissey, PhD
所属市场纳斯达克
员工数量1147
年结日01-02
公司地址1851 Harbor Bay Parkway
城市Alameda
省份加利福尼亚州
国家美国
邮编94502
电话1-650-837-7000
董事高管
- 姓名
- 职务
- 年薪
- Dr. Michael M. Morrissey, PhD
- Director, President and Chief Executive Officer
- 1642.33万
- Dr. Amy C. Peterson, M.D.
- Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
- 736.78万
- Christopher J. Senner
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- 494.76万
- Dr. Dana T. Aftab, PhD
- Chief Scientific Officer and Executive Vice President, Discovery and Translational Research
- 565.31万
- Patrick J. Haley
- Executive Vice President, Commercial
- --
- Jeffrey J. Hessekiel
- Executive Vice President, General Counsel and Secretary
- 456.27万
- Dr. Stelios Papadopoulos,PhD
- Chairman of the Board
- 52.00万
- Dr. Mary C. Beckerle, PhD
- Director
- --
- Dr. Sue Gail Eckhardt, M.D.
- Director
- --
- Tomas J. Heyman
- Independent Director
- 71.62万
- Dr. Maria C. Freire, PhD
- Independent Director
- 48.87万
- Robert Oliver, M.B.A.
- Independent Director
- 71.74万
- Julie Anne Smith
- Independent Director
- 49.09万
- Jack L. Wyszomierski, M.S.
- Independent Director
- 49.10万
- Dr. George H. Poste, D.V.M.,F.R.S.,PhD
- Independent Director
- 48.22万
- David E. Johnson
- Independent Director
- 71.87万